Alan G. Olivero

The Identification of 2-(1<i>H</i>-Indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-<i>d</i>]pyrimidine (GDC-0941) as a Potent, Selective, Orally Bioavailable Inhibitor of Class I PI3 Kinase for the Treatment of Cancer

Adrian Folkes, Khatereh Ahmadi, W. Alderton et al. · Journal of Medicinal Chemistry · 2008 · 739 citations · Full text

Pi3 Kinase, Chemoprevention Strategy, Pharmacotherapy +18

GDC-0980 Is a Novel Class I PI3K/mTOR Kinase Inhibitor with Robust Activity in Cancer Models Driven by the PI3K Pathway

Jeffrey J. Wallin, Kyle A. Edgar, Jane Guan et al. · Molecular Cancer Therapeutics · 2011 · 226 citations

Chemoprevention Strategy, Cancer Biology, Pd Biomarkers +20

Discovery of a Potent, Selective, and Orally Available Class I Phosphatidylinositol 3-Kinase (PI3K)/Mammalian Target of Rapamycin (mTOR) Kinase Inhibitor (GDC-0980) for the Treatment of Cancer

Daniel P. Sutherlin, Linda Bao, Megan Berry et al. · Journal of Medicinal Chemistry · 2011 · 212 citations · Full text

Translational Pharmacology, Pre-clinical Pharmacology, Molecular Pharmacology +20

Discovery of 2-{3-[2-(1-Isopropyl-3-methyl-1<i>H</i>-1,2–4-triazol-5-yl)-5,6-dihydrobenzo[f]imidazo[1,2-<i>d</i>][1,4]oxazepin-9-yl]-1<i>H</i>-pyrazol-1-yl}-2-methylpropanamide (GDC-0032): A β-Sparing Phosphoinositide 3-Kinase Inhibitor with High Unbound Exposure and Robust in Vivo Antitumor Activity

Chudi Ndubaku, Timothy P. Heffron, Steven T. Staben et al. · Journal of Medicinal Chemistry · 2013 · 174 citations · Full text

Drug Target, Unbound Drug Exposure, Pharmacotherapy +21

Discovery of (Thienopyrimidin-2-yl)aminopyrimidines as Potent, Selective, and Orally Available Pan-PI3-Kinase and Dual Pan-PI3-Kinase/mTOR Inhibitors for the Treatment of Cancer

Daniel P. Sutherlin, Deepak Sampath, Megan Berry et al. · Journal of Medicinal Chemistry · 2010 · 131 citations · Full text